Glutamate receptors in schizophrenia and antipsychotic drugs

Neurotransmitter Receptors in Actions of Antipsychotic Medications

Volumn , Issue , 2000, Pages 121-136

  Goff, Donald C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055401039     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (146)

1. Olney, J.W. and Farber, N.B., Glutamate receptor dysfunction and schizophrenia, Arch. Gen. Psychiatry, 52, 998, 1995.
2. Coyle, J.T., The glutamatergic dysfunction hypothesis for schizophrenia, Harvard Rev. Psychiatry, 3, 241, 1996.
3. Goff, D. and Wine, L., Glutamate in schizophrenia: clinical and research implications, Schizophr. Res., 27, 157, 1997.
4. McDonald, J.W. and Johnstone, M.V., Physiological and pathophysiological roles of excitatory amino acids during central nervous system development, Brain Res. Rev., 15, 41, 1990.
5. Kerwin, R.W., Glutamate receptor, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis, Psychol. Med., 13, 547, 1993.
6. Komuro, H. and Rakic, P., Modulation of neuronal migration by NMDA receptors, Science, 260, 95, 1993.
7. Akbarian, S. et al., Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development, Arch. Gen. Psychiatry, 50, 169, 1993.
8. Akbarian, S., Vinuela, A., Kim, J.J., Potkin, S.G., Bunney, W.E., Jr., and Jones, E.G., Distorted distribution of nicotinamideadenine dinucleotidephosphatediaphorase neurons in temporal lobe of schizophrenics implies abnomalous cortical development, Arch. Gen. Psychiatry, 50, 178, 1993.
9. Selemon, L. and Goldman-Rakic, P., The reduced neuropil hypothesis: a circuit based model of schizophrenia, Biol. Psychiatry, 45, 17, 1999.
10. Choi, D.W., Glutamate neurotoxicity and diseases of the nervous system, Neuron, 1, 623, 1988.
11. Coyle, J.T. and Puttfarcken, P., Oxidative stress, glutamate, and neurodegenerative disorders, Science, 262, 689, 1993.
12. Olney, J.W., New mechanisms of excitatory transmitter neurotoxicity, [Review], J. Neural Transm. Suppl., 43(47), 47, 1994.
13. Lipska, B.K. et al., Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat, Brain Res., 585, 1, 1992.
14. Lipska, B.K. et al., Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine, Psychopharmacology, 122, 35, 1995.
15. Weinberger, D., A connectionist approach to the prefrontal cortex, J. Neuropsychiatry, 5, 241, 1993.
16. Carlsson, M. and Carlsson, A., Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson’s disease, Trends Neurosci., 13, 272, 1990.
17. Huntley, G.W., Vickers, J.C., and Morrison, J.H., Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease, Trends Neurosci., 17(2), 536, 1994.
18. Mayer, M.L., Westbrook, G.L., and Guthrie, P.B., Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurons, Nature, 309, 261-263, 1984.
19. Nowak, L. et al., Magnesium gates glutamate-activated channels in mouse central neurons, Nature, 307, 462, 1984.
20. McEntee, W. and Crook, T., Glutamate: its role in learning, memory, and the aging brain, Psychopharmacology, 111, 391, 1993.
21. Grunze, H.C.R. et al., NMDA-dependent modulation of CA1 local circuit inhibition, J. Neurosci., 16(6), 2034, 1996.
22. Fitzgerald, L.W. et al., Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs, J. Neurosci., 15(3), 2453, 1995.
23. Breese, C.R., Freedman, R., and Leonard, S.S., Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers, Brain Res., 674, 82, 1995.
24. Kim, J.S. et al., Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia, Neurosci. Lett., 20, 379, 1980.
25. Bjerkenstedt, L. et al., Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls, Br. J. Psychiatry, 147, 276, 1985.
26. Macciardi, F. et al., Amino acid patterns in schizophrenia: some new findings, Psychiatry Res., 32, 63, 1990.
27. Gattaz, W.F., Gattaz, D., and Beckmann, H., Glutamate in schizophrenics and healthy controls, Arch. Psychiatr. Nervenkr., 231, 221, 1982.
28. Perry, T.L., Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction, Neurosci. Lett., 28, 81, 1982.
29. Tsai, G. et al., Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia, Biol. Psychiatry, 44, 667, 1998.
30. Faustman, W. et al., Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients, Biol. Psychiatry, 45, 68, 1999.
31. Tsai, G. et al., Abnormal excitatory neurotransmitter metabolism in schizophrenic brains, Arch. Gen. Psychiatry, 52, 829, 1995.
32. Deakin, J.F.W. et al., Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia, J. Neurochem., 52, 1781, 1989.
33. Nishikawa, T., Takashima, M., and Toru, M., Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia, Neurosci. Lett., 40, 245, 1983.
34. Kerwin, R.W. et al., Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia, Lancet, 1, 583, 1988.
35. Kerwin, R., Patel, S., and Meldrum, B., Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem, Neuroscience, 39, 25, 1990.
36. Sokolov, B., Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of “neuroleptic-free” schizophrenics: evidence on reversible up-regulation by typical neuroleptics, J. Neurochem., 71, 2454, 1998.
37. Ishimaru, M., Kurumaji, A., and Toru, M., NMDA-associated glycine binding site increases in schizophrenic brains (Letter), Biol. Psychiatry, 32, 379, 1992.
38. Ishimaru, M., Kurumaji, A., and Toro, M., Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis, Biol. Psychiatry, 35, 84, 1994.
39. Harrison, P.J., McLaughlin, D., and Kerwin, R.W., Decreased hippocampal expression of a glutamate receptor gene in schizophrenia, Lancet, 337, 450, 1991.
40. Eastwood, S.L. et al., Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia, Mol. Brain Res., 29, 211, 1995.
41. Akbarian, S., Smith, M.A., and Jones, E.G., Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer’s disease, Huntington’s disease and schizophrenia, Brain Res., 699(2), 297, 1995.
42. Akbarian, S. et al., Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics, J. Neurosci., 16(1), 19, 1996.
43. Luby, E.D. et al., Study of a new schizophrenomimetic drug-sernyl, Arch. Neurol. Psychiatry, 81, 363, 1959.
44. Javitt, D. and Zukin, S., Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry, 148, 1301, 1991.
45. Jentsch, J. and Roth, R., The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia, Neuropsychopharmacology, 20, 201, 1999.
46. Itil, T. et al., Effect of phencyclidine in chronic schizophrenics, Can. Psychiatr. Assoc. J., 12, 209, 1967.
47. Smith, D. et al., Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines, Neuropharmacology, 20, 391, 1981.
48. Byrd, L., Standish, L., and Howell, L., Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs, Eur. J. Pharmacol., 144, 331, 1987.
49. Cohen, B. et al., Comparison of phencyclidine hydrochloride (Sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium, II: symbolic and sequential thinking, Arch. Gen. Psychiatry, 6, 79, 1962.
50. Newcomer, J. et al., Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis, Neuropsychopharmacology, 20, 106, 1999.
51. Krystal, J.H. et al., Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch. Gen. Psychiatry, 51, 199, 1994.
52. Malhotra, A. et al., NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers, Neuropsychopharmacology, 14, 301, 1996.
53. Lahti, A.C. et al., Subanesthetic doses of ketamine stimulate psychosis in schizophrenia, Neuropsychopharmacology, 13, 9, 1995.
54. Malhotra, A. et al., Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics, Neuropsychopharmacology, 17, 141, 1997.
55. Malhotra, A. et al., Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine, Biol. Psychiatry, 42, 664, 1997.
56. Jentsch, J. et al., Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after longterm administration of phencyclidine, Science, 277, 953, 1997.
57. Breier, A. et al., Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers, Am. J. Psychiatry, 154, 805, 1997.
58. Hertzman, M., Reba, R., and Kotlyarove, E., Single photon emission computerized tomography in phencyclidine and related drug abuse, Am. J. Psychiatry, 147, 255, 1990.
59. Wu, J., Buchsbaum, M., and Bunney, W., Jr., Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia, Jpn. J. Psychopharmacol., 11, 47, 1991.
60. Deutch, A.Y. et al., Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response, Eur. J. Pharmacol., 134, 257, 1987.
61. Bowers, M.B.J., Bannon, M.J., and Hoffman, F.J.J., Activation of forebrain dopamine systems by phencyclidine and footshock stress: evidence for distinct mechanisms, Psychopharmacology, 93, 133, 1987.
62. Verma, A. and Moghaddam, B., NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine, J. Neurosci., 16(1), 373, 1996.
63. Yonezawa, Y. et al., Involvement of g-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex, Eur. J. Pharmacol., 341, 45, 1998.
64. Moghaddam, B. et al., Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex, J. Neurosci., 17, 2921, 1997.
65. Moghaddam, B. and Adams, B., Reversal of phencyclidine effects by a group II metabotripic glutamate receptor agonist, Science, 281, 1349, 1998.
66. Svensson, T.H. et al., Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha1-adrenoreceptor antagonism, J. Clin. Psychopharmacol., 15, 11s, 1995.
67. Jentsch, J. et al., Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat, Neuropsychopharmacology, 17, 92, 1997.
68. Lindefors, N., Barati, S., and O’Connor, W., Differential effects of single and repeated ketamine administration on dopamine, serotonin, and GABA transmission in rat prefrontal cortex, Brain Res., 759, 202, 1997.
69. Healy, D.J. and Meador-Woodruff, J.H., Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems, Brain Res., 708, 38, 1996a.
70. Healy, D.J. and Meador-Woodruff, J.H., Dopamine receptor gene expression in hippocampus is differentially regulated by the NMDA receptor antagonist MK-801, Eur. J. Pharmacol., 306, 257, 1996b.
71. Sawaguchi, T. and Goldman-Rakic, P.S., D1 dopamine receptors in prefrontal cortex: involvement in working memory, Science, 251, 947, 1991.
72. Davis, K. et al., Dopamine in schizophrenia: a review and reconceptualization, Am. J. Psychiatry, 148, 1474, 1991.
73. Jentsch, J. et al., Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966, J. Neurosci., 17, 1769, 1997.
74. Scalzo, F. and Holson, R., The ontogeny of behavioral sensitization to phencyclidine, Neurotoxicol. Teratol., 14, 7, 1992.
75. Wolf, M. et al., Low-dose bromocriptine in neuroleptic-resistant schizophrenia: a pilot study, Biol. Psychiatry, 31, 1166, 1992.
76. Xu, X. and Domino, E., Phencyclidine-induced behavioral sensitization, Pharmacol. Biochem. Behav., 47, 603, 1994.
77. Lannes, B. et al., Behavioral, pharmacological, and biochemical effects of acute and chronic administration of ketamine in the rat, Neurosci. Lett., 128, 177, 1991.
78. Jentsch, J., Taylor, J., and Roth, R., Subchronic phencyclidine administration increases mesolimbic dopamine system responsivity and augments stress and amphetamine-induced hyperlocomotion, Neuropsychopharmacology, 19, 105, 1998.
79. Lieberman, J., Sheitman, B., and Kinon, B., Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity, Neuropsychopharmacology, 17, 205, 1997.
80. Grenhoff, J. and Svensson, T.H., Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area, Eur. J. Pharmacol., 233, 79, 1993.
81. Gleason, S. and Shannon, H., Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice, Psychopharmacology, 129, 79, 1997.
82. Freed, W.J. et al., Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice, Psychopharmacology, 71, 291, 1980.
83. Sams-Dodd, F., Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test, Psychopharmacology, 135, 182, 1998.
84. Corbett, R. et al., Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonistinduced behaviors, Psychopharmacology, 120, 67, 1995.
85. Bakshi, V.P., Swerdlow, N.R., and Geyer, M.A., Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response, J. Pharmacol. Exp. Ther., 271, 787, 1994.
86. Bakshi, V. and Geyer, M., Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic drug olanzapine, Psychopharmacology, 122, 198, 1995.
87. Swerdlow, N., Bakshi, V., and Geyer, M., Seroquel restores sensorimotor gating in phencylidinetreated rats, J. Pharmacol. Exp. Ther., 279, 1290, 1996.
88. Johansson, C., Jackson, D., and Svensson, L., The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat, Psychopharmacology, 116, 437, 1994.
89. Swerdlow, N. et al., Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketaminetreated rats, Psychopharmacology, 140, 75, 1998.
90. Olney, J.W. and Farber, N.B., Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity, J. Clin. Psychiatry, 55(9) (Suppl. B), 43, 1994.
91. Farber, N. et al., Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity, Schizophr. Res., 21, 33, 1996.
92. Farber, N.B. et al., Antipsychotic drugs block phencyclidine induced neurotoxicity, Biol. Psychiatry, 34, 119, 1993.
93. Farber, N.B. et al., Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?, Biol. Psychiatry, 38, 788, 1995.
94. Alfredsson, G. and Wiesel, F.A., Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment, Psychopharmacology, 99, 322, 1989.
95. Alfredsson, G. and Wiesel, F.A., Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients, Psychopharmacology, 101, 324, 1990.
96. Evins, A. et al., Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics, J. Neural Transm., 104, 761, 1997.
97. Labarca, R. et al., Effects of haloperidol on CSF glutamate levels in drug-naive schizophrenic patients, Schizophr. Res., 16, 83, 1995.
98. Yamamoto, B.K. and Cooperman, M.A., Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations, J. Neurosci., 14, 4159, 1994.
99. Yamamoto, B.K., Pehek, E.A., and Meltzer, H.Y., Brain region effects of clozapine on amino acid and monoamine transmission, J. Clin. Psychiatry, 55(9) (Suppl. B), 8, 1994.
100. Youngren, K.D. et al., Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment, Neurosci. Lett., 165, 41, 1994.
101. See, R. and Lynch, A., Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats, Eur. J. Pharmacol., 308, 279, 1996.
102. Tsai, G., Goff, D., and Coyle, J., Oxidative stress and glutamatergic hypotheses of tardive dyskinesia, Neurosci. Abstr., 20, 671, 1994.
103. Goff, D.C. et al., Tardive dyskinesia and substrates of energy metabolism in CSF, Am. J. Psychiatry, 152, 1730, 1995.
104. Meshul, C. et al., Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses, J. Neurochem., 67, 1965, 1996.
105. Lidsky, T.I. et al., Anti-glutamatergic effects of clozapine, Neurosci. Lett., 163, 155, 1993.
106. Arvanov, V. et al., Clozapine and haloperidol modulate N-methyl-D-aspartate and non-N-methyl-Daspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro, J. Pharmacol. Exp. Ther., 283(1), 226, 1997.
107. Ossowska, K., Pietraszek, M., and Wardas, J., Further evidence for the subsensitivity of striatal AMPA receptors, induced by chronic haloperidol administration: an autoradiographic study, Naunyn Schmiedebergs Arch. Pharmacol., 354, 384, 1996.
108. Tarazi, F., Florijn, W., and Creese, I., Chronic effects of typical and atypical neuroleptics on glutamate receptor subtypes, Schizophr. Res., 15, 167, 1995.
109. Ulas, J. and Cotman, C., Excitatory amino acid receptors in schizophrenia, Schizophr. Bull., 19, 105, 1993.
110. Banerjee, S.P. et al., Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia, NeuroReport, 6, 2500, 1995.
111. Lidsky, T.I. et al., Glutamatergic mechanisms of antipsychotic drug action, Soc. Neurosci., 22 (Abstr.), 430, 1996.
112. Fletcher, E.J. and MacDonald, J.F., Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur. J. Pharmacol., 235, 291, 1993.
113. McCoy, L. and Richfield, E.K., Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain, Neurosci. Lett., 213, 137, 1996.
114. Coughenour, L.L. and Cordon, J.J., Characterization of haloperidol and trifluperidol as subtypeselective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes, J. Pharmacol. Exp. Ther., 280(2), 584, 1997.
115. Ilyin, V. et al., Subtype-selective inhibition of N-Methyl-D-aspartate receptors by haloperidol, Mol. Pharmacol. 50, 1541, 1996.
116. Reynolds, I. and Miller, R., [3H] MK801 binding to the N-methyl-D-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites, J. Pharmacol. Exp. Ther., 247, 1025, 1988.
117. Healy, D. and Meador-Woodruff, J., Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum, Mol. Brain Res., 47, 331, 1997.
118. Riva, M. et al., Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs, Mol. Brain Res., 50, 136, 1997.
119. Meador-Woodruff, J. et al., Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine, Mol. Psychiatry, 1, 41, 1996.
120. Schneider, J., Wade, T., and Lidsky, T., Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum, NeuroReport, 9(1), 133, 1998.
121. Lawlor, B.A. and Davis, K.L., Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer’s disease?, Biol. Psychiatry, 31, 337, 1992.
122. Waziri, R., Glycine therapy of schizophrenia (Letter), Biol. Psychiatry, 23, 209, 1988.
123. Rosse, R.B. et al., Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study, Clin. Neuropharmacol., 12, 416, 1989.
124. Costa, J. et al., An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics (Letter), J. Clin. Psychopharmacol., 10, 71, 1990.
125. D’Souza, D.C., Charney, D., and Krystal, J., Glycine site agonists of the NMDA receptor: a review, CNS Drug Rev., 1(2), 227, 1995.
126. Javitt, D.C. et al., Amelioration of negative symptoms in schizophrenia by glycine, Am. J. Psychiatry, 151(8), 1234, 1994.
127. Heresco-Levy, U. et al., Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia, Br. J. Psychiatry, 169, 610, 1996.
128. Heresco-Levy, U. et al., Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia, Arch. Gen. Psychiatry, 56, 29, 1999.
129. Tsai, G. et al., D-Serine added to antipsychotics for the treatment of schizophrenia, Biol. Psychiatry, 44, 1081, 1998.
130. Watson, G.B. et al., D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes, Brain Res., 510, 158, 1990.
131. van Berckel, B.N. et al., Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients, Biol. Psychiatry, 40, 1298, 1996.
132. Goff, D.C. et al., Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia, Am. J. Psychiatry, 152, 1213, 1995.
133. Goff, D. et al., A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia, Arch. Gen. Psychol., 56, 21, 1999.
134. Rosse, R. et al., D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia, Clin. Neuropharmacol., 19, 444, 1996.
135. Goff, D.C. et al., D-Cycloserine added to clozapine for patients with schizophrenia, Am. J. Psychiatry, 153, 1628, 1996.
136. Goff, D. et al., A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia, Biol. Psychiatry, 45, 512, 1999.
137. Arai, A. et al., Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus, J. Pharmacol. Exp. Ther., 278, 1, 1996.
138. Sirvio, J. et al., Effects of pharmacologically facilitating glutamatergic transmission in the trisynaptic intrahippocampal circuit, Neuroscience, 74, 1025, 1996.
139. Staubli, U. et al., Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo, Proc. Natl. Acad. Sci. U.S.A., 91, 11158, 1994.
140. Staubli, U., Rogers, G., and Lynch, G., Facilitation of glutamate receptors enhances memory, Proc. Natl. Acad. Sci. U.S.A., 91, 777, 1994.
141. Johnson, S. et al., Synergistic interactions between ampakines and antipsychotic drugs, J. Pharmacol. Exp. Ther., 289, 392, 1999.
142. Goff, D. et al., Ampakine (CX516) added to clozapine in schizophrenia: preliminary safety and efficacy data, (poster) presented at Am. College Neuropsychopharmacology, San Juan, Puerto Rico, 1998.
143. Goff, D. et al., A preliminary dose escalation trial of CX516 (ampakine) added to clozapine in schizophrenia, Schizophr. Res., 36, 280, 1999.
144. Johnson, S.A., Luu, N.T., Herbst, T.A., Knapp, R., Lutz, D., Arai, A., Rogers, G.A., and Lynch, D., Synergistic interactions between ampakines and antipsychotic drugs, J. Pharmacol. Exp. Ther., 289, 392, 1999.
145. Aparicio-Legarza, M.I. et al., Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients, Neurosci. Lett., 241, 143, 1998.
146. Simpson, M.D.C. et al., Regionally selective deficits in uptake sites for glutamate and gammaaminobutyric acid in the basal ganglia in schizophrenia, Psychiatry Res., 42, 273, 1992.